Alvotech Registered Aktie

7,36 EUR -0,10 EUR -1,34 %

22.07.2025

BMN

8,70 USD +0,05 USD +0,58 %

22.07.2025

BTT

Aktien, ETFs, Sparpläne & Kryptos zu Top-Konditionen beim Testsieger von finanztip.de handeln!

JETZT LOSLEGEN

Du hast schon ein ZERO-Konto? Direkt handeln bei ZERO!Bei einem anderen Broker handeln Smartphone

Marktkap.2,23 Mrd. EUR

Div. Rendite0,00%

WKNA3DK8U

ISINLU2458332611

SymbolALVO

Alvotech Registered Aktien News

Sortieren:Datum Meistgelesen

25.09.24GlobeNewswireAlvotech Initiates Confirmatory Patient Study for AVT16, a Proposed Biosimilar to Entyvio®

26.08.24GlobeNewswireAlvotech to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference

15.08.24GlobeNewswireAlvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of 2024

15.08.24GlobeNewswireEuropean Medicines Agency Confirms Acceptance of Marketing Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)

01.08.24GlobeNewswireAlvotech to Report Financial Results for the First Half of 2024 on August 15, 2024, and Host Conference Call on August 16, 2024, at 8:00 am ET

22.07.24GlobeNewswireSTADA and Alvotech launch Uzpruvo, the first approved ustekinumab biosimilar to Stelara, across Europe

11.07.24GlobeNewswireAlvotech Announces Closing of Private Debt Financing

02.07.24GlobeNewswireAlvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®

01.07.24GlobeNewswireAlvotech Issues New Shares to Holders of Convertible Bonds

01.07.24GlobeNewswireAlvotech Announces Record Preliminary Results for Revenues and EBITDA for the Second Quarter of 2024

26.06.24GlobeNewswireAlvotech Receives Conversion Notices for Majority of Convertible Bonds

18.06.24GlobeNewswireAlvotech and Advanz Pharma Sign Commercialization Agreement for Proposed Biosimilar to Eylea® LD/HD in Europe

11.06.24GlobeNewswireAlvotech and STADA add to Strategic Alliance through Denosumab Partnership

07.06.24GlobeNewswireAlvotech Announces Strategic Refinancing Agreement

29.05.24GlobeNewswireAlvotech to Participate in Jefferies Healthcare Conference in New York, June 5-6, 2024

21.05.24GlobeNewswireAlvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update

21.05.24GlobeNewswireAlvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a biosimilar candidate to Prolia® & Xgeva® in the U.S., Europe and UK

21.05.24GlobeNewswireTeva and Alvotech Announce SIMLANDI® (adalimumab-ryvk) Injection Now Available in the U.S.

15.05.24GlobeNewswireAlvotech S.A. Annual General Meeting to be held June 7, 2024

13.05.24GlobeNewswireAlvotech Announces Webcast of First Quarter 2024 Financial Results on May 22, 2024, at 8:00 am EDT (12 noon GMT)

02.05.24GlobeNewswireAlvotech Announces Participation at BofA Securities Healthcare Conference 2024

30.04.24GlobeNewswireU.S. Commercialization Agreement with Quallent to Drive Patient Savings with First High-Concentration Citrate-Free Interchangeable Biosimilar to Humira® (adalimumab)

24.04.24GlobeNewswireAlvotech Announces Topline Results from a Confirmatory Clinical Study for AVT05, a Proposed Biosimilar for Simponi® (golimumab)

19.04.24GlobeNewswireAlvotech signs U.S. agreement to expand access for newly approved high-concentration interchangeable biosimilar to Humira® (adalimumab)

16.04.24GlobeNewswireAlvotech and Teva Announce U.S. FDA Approval of SELARSDI™ (ustekinumab-aekn), biosimilar to Stelara® (ustekinumab)

03.04.24GlobeNewswireAlvotech Hosts Audio Call for Investors at 8:15 am EDT on April 3, 2024

22.03.24GlobeNewswireAlvotech Announces Increase in Number of Own Shares

20.03.24GlobeNewswireAlvotech Reports Financial Results for Full Year 2023 and Provides a Business Update

05.03.24GlobeNewswireAlvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET

29.02.24GlobeNewswireAlvotech Appoints Interim Chief Quality Officer

26.02.24GlobeNewswireAlvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share

24.02.24GlobeNewswireAlvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®

15.02.24GlobeNewswireAlvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab)

29.01.24GlobeNewswireAlvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®

19.01.24GlobeNewswireAlvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04

10.01.24GlobeNewswireSTADA and Alvotech Secure Approval for Uzpruvo, Europe’s First Ustekinumab Biosimilar to Stelara

03.01.24GlobeNewswireAlvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea® (aflibercept)

29.11.23GlobeNewswireAlvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®

28.11.23GlobeNewswireAlvotech Reports Financial Results for First Nine Months of 2023 and Provides Business Update

21.11.23GlobeNewswireAlvotech to Report Financial Results for the First Nine Months of 2023 on November 28, 2023, and Host Business Update Conference Call on November 29, 2023, at 8:00 am ET

Alvotech Registered News

Alvotech Registered News: auf dieser Seite finden Sie alle Alvotech Registered News und Nachrichten zur Alvotech Registered Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Alvotech Registered News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Alvotech Registered News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.